Melissa Ronan
About Melissa Ronan
Melissa Ronan serves as the Prism Screening Lead at the Broad Institute of MIT and Harvard, where she has worked since 2020. With over a decade of experience in drug discovery and high throughput screening, she has held various roles at Chromocell Corporation and has a strong academic background in Biomedical Sciences and Psychology.
Current Role at Broad Institute
Melissa Ronan serves as the PRISM Screening Lead at the Broad Institute of MIT and Harvard. She has held this position since 2020, contributing to the institute's efforts in drug discovery and high throughput screening. Her role involves overseeing the PRISM platform, which is integral to the development of new therapeutic strategies.
Previous Experience at Chromocell Corporation
Prior to her current role, Melissa Ronan worked at Chromocell Corporation in various capacities from 2008 to 2018. She began as a Laboratory Assistant in Cell Culture, then progressed to Associate Scientist in Robotics, and later served as Senior Associate Scientist in Assay Development. During her tenure, she developed functional cell-based assays, enhancing the company's drug discovery processes.
Education and Expertise in Biomedical Sciences
Melissa Ronan earned her Master of Science (M.S.) in Biomedical Sciences from Rutgers, The State University of New Jersey-Newark, completing her studies from 2013 to 2015. She also holds a Bachelor of Arts (B.A.) in Psychology from Rutgers University. Her educational background supports her expertise in laboratory automation and molecular biology.
Experience in Drug Discovery and High Throughput Screening
With over a decade of experience in drug discovery and high throughput screening, Melissa Ronan has developed a strong foundation in the field. Her work includes data analysis and tissue culture, which are critical components of her research and development efforts in the pharmaceutical industry.
Professional Background and Career Progression
Melissa Ronan's professional journey began in 2008 at Chromocell Corporation, where she gained hands-on experience in laboratory settings. Over the years, she advanced through various roles, culminating in her current leadership position at the Broad Institute. Her career reflects a commitment to advancing scientific research and drug development.